Currently, three members of the CYP3A family are identified as involved in the polymorphism, namely CYP3A4, CYP3A5, and CYP3A7. The CYP3A43 member does not contribute much to the polymorphism and metabolism of drugs used in the treatment of nephrotic syndrome. This evidence concerns the gene CYP3A5 and nephrotic syndrome.